HROWHarrow, Inc.

$29.36-34% 1Y

$29.36

$29.0352 weeks$54.80

HROW in its own filings

HROW's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

402

Events found in the filings · across 867 filings · the record starts in 2006

Hard flags: 3
Hard flags
Most recent filing: Oct 5, 2026
Most recent filing · Form 8-K
Record starts: Dec 28, 2006
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 9, 2026
Bankruptcy or receivershiphistorical: 2011-06-27
Change in certifying accountant4 occurrences: 2025-09-19
Late periodic report2 occurrences: 2025-03-17
Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares: 2025-10-10
Material impairmenthistorical: 2019-08-30
SEC comment-letter activity17 occurrences: 2022-06-01

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 5, 2026As previously disclosed, on August 3, 2026, Harrow, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Original Purchase Agreement") with Viatris Inc. ("Viatris") relating to the acquisition of TYRVAYA ® (varenicline solution) nasal spray 0.03 mg ("TYRVAYA"), a cholinergic agonist indicated for the …Material agreement entered · Form 8-K
Sep 4, 2026Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”)Director or officer change · Form 8-K
Aug 10, 2026Announces Second Quarter 2026 Financial Results.Earnings release · press release
Aug 6, 2026On August 3, 2026, Harrow, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Viatris Inc. (“Viatris”), pursuant to which the Company agreed to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg (“TYRVAYA”), a cholinergic agonist indicated for …Material agreement entered · Form 8-K
May 11, 2026Announces First Quarter 2026 Financial Results.Earnings release · press release
Mar 27, 2026Purchase Agreement On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of …Material agreement entered · Form 8-K
Mar 24, 2026On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”) in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional …Other event · Form 8-K
Mar 24, 2026On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release to announce the launch of its offer to sell $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”) in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional …Other event · Form 8-K
Mar 2, 2026Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance.Earnings release · press release